Human Race VC

Personalized headache and migraine treatment by experts, offering fast access to specialized care without long wait times.

MyndLift offers therapist-guided home neurofeedback solutions to help individuals optimize their brain health and cognitive performance through personalized training and brain tracking.

Siren is a health technology company that uses novel medical devices and remote patient monitoring to improve patient outcomes, specifically focusing on diabetic foot health through their innovative Siren Socks.

Invests in early-stage startups in highly regulated industries, combining VC, political consulting, and equity-for-service regulatory execution under one umbrella so founders can pay equity for lobbying and regulatory work. Tusk Venture Partners is the world's first VC fund that invests solely in early-stage startups in highly regulated industries, turning regulatory and political risk into a competitive advantage by backing companies where solving a gating regulatory issue can materially unlock growth and valuation.

Early-stage investor spanning service-heavy care delivery and deep neuro/bio/AR frontier tech. Arkitekt Ventures deliberately spans both service-heavy care delivery companies and deep frontier neuro/bio/AR technologies, reflecting a thesis that the future of care sits at the intersection of physical clinics and bleeding-edge tech. The fund shows an unusually high concentration in brain- and nervous-system related innovation, suggesting a distinctive neuro + AI + delivery wedge inside healthtech.

Small specialist team of physicians and operator-investors in a pharma–VC joint venture, focused exclusively on personalized medicine, data analytics and clinically validated digital therapeutics, with early DTx track record. DigiTx Partners is a venture capital fund launched as a joint venture between global pharma company Astellas Pharma and life-sciences VC MPM Capital, exclusively focused on digital health investments around three specific pillars: Personalized Medicine, Data Analytics, and Digital Therapeutics. The fund operates as a small specialist team combining physicians and operators with investing backgrounds, known for being early investors in prescription and clinically validated digital therapeutics.

Seed-stage co-investor alongside specialist seed investors. Reserves 25% of capital for follow-on investments. Provides portfolio company access to 500,000+ member network for hiring, customer introductions, and expertise. Focuses on deeptech and AI sectors across early-stage funding rounds.

Virtue VC exclusively focuses on pre-seed and seed healthcare investments, making decisions in 7-10 days and typically being the first investor to commit with $500K-$2M checks. The fund backs founders who radically re-architect the healthcare value chain rather than make incremental improvements, often supporting non-traditional founder profiles tackling intractable healthcare problems.